Evidence map›Paper›PMID 27432473›Full record

ArticleScientific reports2016

Cannabinoid receptor subtype 2 (CB2R) agonist, GW405833 reduces agonist-induced Ca(2+) oscillations in mouse pancreatic acinar cells.

Zebing Huang, Haiyan Wang, Jingke Wang, Mengqin Zhao, Nana Sun, Fangfang Sun, Jianxin Shen, Haiying Zhang, Kunkun Xia, Dejie Chen and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Role of the Endocannabinoid System in Fibromyalgia.Current issues in molecular biology · 2025
    Review
  2. Article
  3. Review
  4. Indole compounds withMedChemComm · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Zebing HuangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, and Key Laboratory of Viral Hepatitis, Hunan Province, Changsha 410008, China.
Haiyan WangDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Jingke WangDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Mengqin ZhaoDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Nana SunDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Fangfang SunDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Jianxin ShenDepartment of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Haiying ZhangIntramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA.
Kunkun XiaDepartments of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ 85013, USA.
Dejie ChenDepartments of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ 85013, USA.
Ming GaoDepartments of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ 85013, USA.
Ronald P HammerDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ 85004, USA.
Qingrong LiuIntramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA.
Zhengxiong XiIntramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA.
Xuegong FanDepartment of Infectious Diseases, Xiangya Hospital, Central South University, and Key Laboratory of Viral Hepatitis, Hunan Province, Changsha 410008, China.
Jie WuDepartment of Infectious Diseases, Xiangya Hospital, Central South University, and Key Laboratory of Viral Hepatitis, Hunan Province, Changsha 410008, China.
Shantou University · CNNational Institute on Drug Abuse · USShantou University Medical College · CNBarrow Neurological Institute · USCentral South University · CNSt. Joseph's Hospital and Medical Center · USUniversity of Arizona · USXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence demonstrates that the blockade of intracellular Ca(2+) signals may protect pancreatic acinar cells against Ca(2+) overload, intracellular protease activation, and necrosis. The activation of cannabinoid receptor subtype 2 (CB2R) prevents acinar cell pathogenesis in animal models of acute pancreatitis. However, whether CB2Rs modulate intracellular Ca(2+) signals in pancreatic acinar cells is largely unknown. We evaluated the roles of CB2R agonist, GW405833 (GW) in agonist-induced Ca(2+) oscillations in pancreatic acinar cells using multiple experimental approaches with acute dissociated pancreatic acinar cells prepared from wild type, CB1R-knockout (KO), and CB2R-KO mice. Immunohistochemical labeling revealed that CB2R protein was expressed in mouse pancreatic acinar cells. Electrophysiological experiments showed that activation of CB2Rs by GW reduced acetylcholine (ACh)-, but not cholecystokinin (CCK)-induced Ca(2+) oscillations in a concentration-dependent manner; this inhibition was prevented by a selective CB2R antagonist, AM630, or was absent in CB2R-KO but not CB1R-KO mice. In addition, GW eliminated L-arginine-induced enhancement of Ca(2+) oscillations, pancreatic amylase, and pulmonary myeloperoxidase. Collectively, we provide novel evidence that activation of CB2Rs eliminates ACh-induced Ca(2+) oscillations and L-arginine-induced enhancement of Ca(2+) signaling in mouse pancreatic acinar cells, which suggests a potential cellular mechanism of CB2R-mediated protection in acute pancreatitis.

Indexed as

AcetylcholineAcinar CellsAnimalsArginineCalciumCalcium SignalingCholinergic AgonistsIndolesMaleMice, Inbred C57BLMice, KnockoutMorpholinesPancreasReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB21-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indoleAcetylcholineArginineCalciumCholinergic AgonistsIndolesMorpholinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID27432473
PMCPMC4949433
OpenAlexW2504789800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.